ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay...Read more
100 - 249
N/A
acelyrin.com
Private
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by ACELYRIN
Are you looking for the decision-makers at ACELYRIN? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover ACELYRIN’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDiscover ACELYRIN alternatives or similar companies to benchmark and competitors market analysis. Build a competitive intelligence sales and marketing strategy based on the data and stand out in the market.
ALLIANCE SURGICAL CARE INC
0 - 9
Alliance
N/A
N/A
N/A
OMID HAMID MD INC.
0 - 9
Agoura Hills
N/A
N/A
N/A
N/A
Ivington CofE Primary School
100 - 249
Leominster
ivington.hereford.sch.uk
N/A
N/A
Parallax Capital Partners
100 - 249
Laguna Hills
parallaxcap.com
Private
N/A
Paulina Equities
0 - 9
Chicago
N/A
N/A
N/A
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are ACELYRIN latest news, alerts and updates.
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the closing of its previously announced upsized initial public offering of 34,
9 May 2023
Acelyrin prices IPO at high end of range, increases share count again
Acelyrin (NASDAQ:SLRN) announced the pricing of its initial public offering. The late-stage biopharma company priced its IPO of 30M shares at $18 per share, at the high end of its proposed range. From the offering,
5 May 2023
ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering
ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the pricing of its upsized initial public offering of 30,
4 May 2023
Acelyrin Begins Rollout Of U.S. IPO Plan
ACELYRIN, Inc. has filed to raise development funding via a U.S. IPO. Click here for our take on the upcoming SLRN IPO and the prospects.
14 Apr 2023
Acelyrin files to go public in rare sign of biotech IPO
California biotech Acelyrin has filed to go public, a rare attempt to access the stock markets after a year of stock declines and cutbacks across the industry. Acelyrin was founded by veterans of Horizon Therapeutics in 2020,
13 Apr 2023
Explore frequently asked questions about ACELYRIN’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
What is ACELYRIN's official website?
The official website of ACELYRIN is acelyrin.com You can find their contact number, email address, and headquarters by clicking here.
How many employees are working at ACELYRIN?
What industry is ACELYRIN in?
What is ACELYRIN's tech stack?
Where are ACELYRIN's headquarters?